HANALL BIOPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37,300 KRW | +2.05% |
|
+9.87% | -15.80% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,857,720 | 1,919,220 | 1,077,892 | 902,290 | 2,245,705 | 1,890,853 | - | - |
| Enterprise Value (EV) 2 | 1,763 | 1,829 | 998.7 | 859.7 | 2,246 | 1,863 | 1,829 | 1,815 |
| P/E ratio | 96.8 x | 97.2 x | 121 x | 3,560 x | 642 x | 717 x | 177 x | 73.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17.1 x | 21.7 x | 10.6 x | 8.2 x | 16.6 x | 13.2 x | 11.3 x | 9.45 x |
| EV / Revenue | 16.3 x | 20.6 x | 9.83 x | 7.82 x | 16.6 x | 13 x | 10.9 x | 9.07 x |
| EV / EBITDA | 89 x | 207 x | 77.9 x | 189 x | - | 266 x | 109 x | 54.2 x |
| EV / FCF | 86.9 x | -1,120 x | -265 x | 38.4 x | - | 310 x | 1,770 x | 69 x |
| FCF Yield | 1.15% | -0.09% | -0.38% | 2.6% | - | 0.32% | 0.06% | 1.45% |
| Price to Book | 12.3 x | 12.7 x | 6.59 x | 5.38 x | - | 10.7 x | 9.77 x | 7.7 x |
| Nbr of stocks (in thousands) | 51,177 | 51,179 | 51,206 | 50,690 | 50,693 | 50,693 | - | - |
| Reference price 3 | 36,300 | 37,500 | 21,050 | 17,800 | 44,300 | 37,300 | 37,300 | 37,300 |
| Announcement Date | 16/01/20 | 19/01/21 | 18/01/22 | 19/01/23 | 24/01/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 108.5 | 88.6 | 101.6 | 110 | 134.9 | 143.6 | 167.5 | 200 |
| EBITDA 1 | 19.8 | 8.829 | 12.82 | 4.558 | - | 7 | 16.84 | 33.5 |
| EBIT 1 | 17.09 | 5.935 | 10.1 | 1.506 | 2.211 | 3.6 | 13.42 | 29.5 |
| Operating Margin | 15.76% | 6.7% | 9.94% | 1.37% | 1.64% | 2.51% | 8.01% | 14.75% |
| Earnings before Tax (EBT) 1 | 17.46 | 19.57 | 8.702 | 1.929 | 3.203 | 5.86 | 14.86 | 32 |
| Net income 1 | 19.17 | 19.76 | 10 | 1.988 | 3.509 | 2.6 | 10.96 | 26.5 |
| Net margin | 17.68% | 22.31% | 9.84% | 1.81% | 2.6% | 1.81% | 6.54% | 13.25% |
| EPS 2 | 375.0 | 386.0 | 174.0 | 5.000 | 69.00 | 52.00 | 211.0 | 505.5 |
| Free Cash Flow 3 | 20,279 | -1,633 | -3,766 | 22,374 | - | 6,000 | 1,033 | 26,300 |
| FCF margin | 18,698.28% | -1,843.1% | -3,706.93% | 20,340.98% | - | 4,179.44% | 616.92% | 13,150% |
| FCF Conversion (EBITDA) | 102,393.28% | - | - | 490,829.07% | - | 85,714.29% | 6,136.18% | 78,507.46% |
| FCF Conversion (Net income) | 105,759.31% | - | - | 1,125,211.15% | - | 230,769.23% | 9,428.22% | 99,245.28% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 16/01/20 | 19/01/21 | 18/01/22 | 19/01/23 | 24/01/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25.47 | 24.88 | 23.99 | 26.25 | 29.64 | 30.12 | 28.8 | 41.42 | 33 | 31.72 | 34.1 | 34.4 | 37.5 | 35.9 |
| EBITDA | - | - | - | - | - | - | - | 8.589 | 0.6727 | - | - | - | - | - |
| EBIT 1 | 2.207 | 0.9244 | -0.592 | 0.6815 | 0.6218 | 0.7943 | -1.738 | 7.997 | 0.1 | -4.264 | - | 0.4 | 1.4 | 1.8 |
| Operating Margin | 8.66% | 3.71% | -2.47% | 2.6% | 2.1% | 2.64% | -6.04% | 19.31% | 0.3% | -13.44% | - | 1.16% | 3.73% | 5.01% |
| Earnings before Tax (EBT) | 2.06 | 0.3048 | -0.0148 | 0.579 | 0.7344 | 0.6308 | - | 8.203 | 0.5108 | - | - | - | - | - |
| Net income 1 | 2.06 | -0.9503 | -0.083 | -0.0772 | 0.7344 | -0.3229 | -1.254 | 7.306 | 0.3 | -2.863 | -0.3 | 0.6 | 1.3 | 1.6 |
| Net margin | 8.09% | -3.82% | -0.35% | -0.29% | 2.48% | -1.07% | -4.35% | 17.64% | 0.91% | -9.03% | -0.88% | 1.74% | 3.47% | 4.46% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 15/11/21 | 18/01/22 | 28/04/22 | 16/08/22 | 29/11/22 | 19/01/23 | 15/05/23 | 26/07/23 | 26/10/23 | 24/01/24 | 30/04/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 94.9 | 90.2 | 79.2 | 42.6 | - | 28 | 61.6 | 76 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | 20,279 | -1,633 | -3,766 | 22,374 | - | 6,000 | 1,033 | 26,300 |
| ROE (net income / shareholders' equity) | 14.3% | 13.4% | 5.78% | 1.19% | 1.98% | 1.45% | 5.44% | 11.1% |
| ROA (Net income/ Total Assets) | 10.6% | 10.6% | 4.25% | 0.12% | - | 1.1% | 4.26% | 8.55% |
| Assets 1 | 180.9 | 187.1 | 235.3 | 1,629 | - | 236.4 | 257.3 | 309.9 |
| Book Value Per Share 3 | 2,946 | 2,946 | 3,193 | 3,311 | - | 3,494 | 3,818 | 4,844 |
| Cash Flow per Share 3 | 400.0 | 18.10 | - | - | - | 128.0 | 176.0 | 202.0 |
| Capex 1 | 2.12 | 2.56 | 4.61 | 2.83 | - | 3.1 | 3.33 | 3 |
| Capex / Sales | 1.96% | 2.89% | 4.53% | 2.57% | - | 2.16% | 1.99% | 1.5% |
| Announcement Date | 16/01/20 | 19/01/21 | 18/01/22 | 19/01/23 | 24/01/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
37,300
KRW
Average target price
43,600
KRW
Spread / Average Target
+16.89%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.80% | 1.38B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- A009420 Stock
- Financials Hanall Biopharma Co., Ltd.
